Investor Presentaiton

Sartorius Group Integrated services and technologies for all types of biopharmaceuticals Vaccines 20 20 mAbs Regenerative medicine Engineered tissue Bioconjugates ■ ~95% of BPS revenue generated with bio/pharma customers ■ Solutions for the production of all biotechnologically derived drugs and cell derivatives ■ Antibodies are most relevant; strong position in vaccines as well New modalities such as cell and gene therapies and viral vectors with increasing relevance SARTORIUS

View entire presentation